Literature DB >> 25676418

Chlamydophila psittaci-negative ocular adnexal marginal zone lymphomas express self polyreactive B-cell receptors.

D Zhu1, S Bhatt2, X Lu1, F Guo1, H Veelken3, D K Hsu4, F-T Liu5, S Alvarez Cubela6, K Kunkalla7, F Vega7, J R Chapman-Fredricks7, I S Lossos2.   

Abstract

The pathogenesis of Chlamydophila psittaci-negative ocular adnexal extranodal marginal zone lymphomas (OAEMZLs) is poorly understood. OAEMZLs are monoclonal tumors expressing a biased repertoire of mutated surface immunoglobulins. Antigenic activation of the B-cell receptor (BCR) may have a role in the pathogenesis of these lymphomas. We have analyzed the reactivity of recombinant OAEMZL immunoglobulins. OAEMZL antibodies reacted with self-human antigens, as demonstrated by enzyme-linked immunosorbent assays, HEp-2 immunofluorescence and human protein microarrays. All the analyzed recombinant antibodies (rAbs) exhibited polyreactivity by comprehensive protein array antibody reactivity and some rAbs also demonstrated rheumatoid factor activity. The identity of several reactive antigens was confirmed by microcapillary reverse-phase high-performance liquid chromatography nano-electrospray tandem mass spectrometry. The tested rAbs frequently reacted with shared intracellular and extracellular self-antigens (for example, galectin-3). Furthermore, these self-antigens induced BCR signaling in B cells expressing cognate surface immunoglobulins derived from OAEMZLs. These findings indicate that interactions between self-antigens and cognate OAEMZL tumor-derived BCRs are functional, inducing intracellular signaling. Overall, our findings suggest that self-antigen-induced BCR stimulation may be implicated in the pathogenesis of C. psittaci-negative OAEMZLs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25676418     DOI: 10.1038/leu.2015.39

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  45 in total

1.  Anti-D and anti-i activities are inseparable in V4-34-encoded monoclonal anti-D: the same framework 1 residues are required for both reactivities.

Authors:  Susan J Thorpe; Christine Ball; Bernard Fox; Keith M Thompson; Robin Thorpe; Adrian Bristow
Journal:  Transfusion       Date:  2008-03-12       Impact factor: 3.157

2.  Circulating IgG response to stromelysin-3, collagenase-3, galectin-3 and mesothelin in patients with pharynx/larynx squamous cell carcinoma.

Authors:  B Suarez-Alvarez; M M Garcia Suarez; M E Argüelles; A Sampedro; C Alvarez Marcos; E Mira; F A Van den Brul; F T Liu; P S Chowdhury; J R de los Toyos
Journal:  Anticancer Res       Date:  2001 Sep-Oct       Impact factor: 2.480

3.  Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin.

Authors:  E Roggero; E Zucca; C Mainetti; F Bertoni; C Valsangiacomo; E Pedrinis; B Borisch; J C Piffaretti; F Cavalli; P G Isaacson
Journal:  Hum Pathol       Date:  2000-02       Impact factor: 3.466

4.  Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin.

Authors:  Charles C Chu; Rosa Catera; Lu Zhang; Sebastien Didier; Briana M Agagnina; Rajendra N Damle; Matthew S Kaufman; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2010-01-28       Impact factor: 22.113

5.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Authors:  Hugo Mouquet; Johannes F Scheid; Markus J Zoller; Michelle Krogsgaard; Rene G Ott; Shetha Shukair; Maxim N Artyomov; John Pietzsch; Mark Connors; Florencia Pereyra; Bruce D Walker; David D Ho; Patrick C Wilson; Michael S Seaman; Herman N Eisen; Arup K Chakraborty; Thomas J Hope; Jeffrey V Ravetch; Hedda Wardemann; Michel C Nussenzweig
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

Review 6.  Galectin-3--a jack-of-all-trades in cancer.

Authors:  Anna U Newlaczyl; Lu-Gang Yu
Journal:  Cancer Lett       Date:  2011-09-17       Impact factor: 8.679

7.  Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins.

Authors:  Vanessa J Craig; Isabelle Arnold; Christiane Gerke; Minh Q Huynh; Thomas Wündisch; Andreas Neubauer; Christoph Renner; Stanley Falkow; Anne Müller
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

8.  Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.

Authors:  Soung-Chul Cha; Hong Qin; Shibichakravarthy Kannan; Seema Rawal; Leticia S Watkins; Flavio E Baio; Weiguo Wu; Juliana Ong; Jinsong Wei; Benjamin Kwak; Sang Kim; Michael S Popescu; Daniel S Paick; Kunhwa Kim; Amber Luong; Richard E Davis; Harry W Schroeder; Larry W Kwak; Sattva S Neelapu
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity.

Authors:  Richard J Bende; Wilhelmina M Aarts; Robert G Riedl; Daphne de Jong; Steven T Pals; Carel J M van Noesel
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

View more
  7 in total

Review 1.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

2.  Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Authors:  June H Myklebust; Joshua Brody; Holbrook E Kohrt; Arne Kolstad; Debra K Czerwinski; Sébastien Wälchli; Michael R Green; Gunhild Trøen; Knut Liestøl; Klaus Beiske; Roch Houot; Jan Delabie; Ash A Alizadeh; Jonathan M Irish; Ronald Levy
Journal:  Blood       Date:  2016-12-23       Impact factor: 22.113

3.  The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.

Authors:  Marco Magistri; Lanie E Happ; Jeremy Ramdial; XiaoQing Lu; Vasileios Stathias; Kranthi Kunkalla; Nitin Agarwal; Xiaoyu Jiang; Stephan C Schürer; Sander R Dubovy; Jennifer R Chapman; Francisco Vega; Sandeep Dave; Izidore S Lossos
Journal:  Cancer Res Commun       Date:  2021-10-13

4.  Novel GPR34 and CCR6 mutation and distinct genetic profiles in MALT lymphomas of different sites.

Authors:  Sarah Moody; Joe Sneath Thompson; Shih-Sung Chuang; Hongxiang Liu; Markus Raderer; George Vassiliou; Iwona Wlodarska; Fangtian Wu; Sergio Cogliatti; Alistair Robson; Margaret Ashton-Key; Yingwen Bi; John Goodlad; Ming-Qing Du
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 5.  Recent Advances in the Genetic of MALT Lymphomas.

Authors:  Juan José Rodríguez-Sevilla; Antonio Salar
Journal:  Cancers (Basel)       Date:  2021-12-30       Impact factor: 6.639

Review 6.  The Biology of Ocular Adnexal Marginal Zone Lymphomas.

Authors:  Patricia Johansson; Anja Eckstein; Ralf Küppers
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

7.  The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma.

Authors:  Manuel Montesinos-Rongen; Monica Terrao; Caroline May; Katrin Marcus; Ingmar Blümcke; Martin Hellmich; Ralf Küppers; Anna Brunn; Martina Deckert
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.